Articles On Orthocell (ASX:OCC)

Orthocell has been approved to start selling its dental bone repair product Striate+ into the $US65 million ($109m) Brazilian market. 

Orthocell says FDA approval for its Remplir nerve regeneration conduit was timely in more ways than one The approval leverages the $80 million Orthocell spent to develop its collagen-based Celgro platform Inspired by its Australian experie...

Tylah Tully chats with Orthocell’s (ASX:OCC) managing director and CEO Paul Anderson to talk through the company’s major milestone, after 10 year its received FDA approval for its nerve repair product Remplir. But its plans for global expan...

 Truscreen and Mesoblast say: we won’t be ‘tariffed’ Orthocell girds for US Remplir rollout Pacific Edge sales slump amid reimbursement uncertainties   Post Liberation Day, announcements are flowing from US-exposed life sciences companie...

The ASX dividend stock Sonic Healthcare Ltd (ASX: SHL) has dropped 43% since the COVID-19 peak of December 2021. This business provides pathology services for patients in a number of countries, including Australia, the UK, Germany, Switzerl...

Last Friday, it was announced that ASX All Ords company Orthocell Ltd (ASX: OCC) had received approval from the Food and Drug Administration (FDA) to sell its nerve product Remplir in the United States. For investors, this news had been...

Since US President Donald Trump unveiled his tariffs last week, very few ASX companies have escaped the broad based market sell off. Based on share price reactions alone, it isn't obvious which companies are directly impacted by Trump's tar...

ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir  HealthIn...

It was a calamitous end to a calamitous week for the S&P/ASX 200 Index (ASX: XJO) this Friday. The ongoing fallout from President Donald Trump's new tariffs once again smashed the ASX 200 today. T...

The S&P/ASX 200 Index (ASX: XJO) plummeted by 191.9 points or 2.44% on Friday to finish the week at 7,667.8 points. Uncertainty about how the newly announced reciprocal US tariffs will impact ASX 200 shares fuelled today's dive....

ASX drops heavily as Trump’s tariffs spark chaos Energy stocks hit hard Breville and Ansell scramble to neutralise tariffs   The ASX copped another big drop on Friday, tumbling 2.44% as global markets went into freefall. For the week, the...

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these...

Headlines The ASX healthcare sector has seen notable activity with updates from Mesoblast Limited and Orthocell Limited. U.S. trade policies continue to impact various industries, including mining and energy companies listed on the ASX...

The ASX has been down 1.5% at 7,739 points this morning. There’s been carnage on the ASX and the Energy sector has been enduring a bloodbath, followed by IT and Utilities. Staples and Health Care are the only sectors in positive terri...

The S&P/ASX 200 Index (ASX: XJO) is having a tough finish to the week. In afternoon trade, the benchmark index is down 1.45% to 7,743.4 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they...

WA biotech Orthocell has received US Food and Drug Administration clearance for its flagship nerve repair product.

Look, I'm going to keep this short. Which… is uncommon for me, and might be a relief for you.  Two things: First, the ASX is down 1.5% right now, after the US markets fell almost 5% overnight. No, I didn't predict it, but I did write so...

QBE Insurance Group Ltd (ASX: QBE) shares could be in the buy zone right now. That's the view of analysts at Macquarie, which are feeling bullish on the insurance giant. Let's dig deeper into why the broker is tipping this blue chip as a bu...

The world now knows what President Trump had in mind for his Liberation Day – tariffs on almost every country at a rate of at least 10%. For countries like China, the EU, and Vietnam, Trump decided to impose much heavier tariffs, which the...

S&P/ASX 200 Index (ASX: XJO) shares fell 0.94% yesterday as the market digested the 'Liberation Day' reciprocal US tariffs. The US Government announced a range of new duties on imported products manufactured outside the country....

Orthocell Ltd (ASX: OCC) is an Australian medical technology company focused on developing and commercialising innovative regenerative medicine treatments.  Over the last 12 months its share price has skyrocketed, up more than 260% in t...

The ASX has pared losses and has been down 1.25% at 7,835 points this morning. Information Technology has been the biggest loser, followed by Energy and Real Estate. Staples has been the only sector to buck the trend and gain ground....

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

S&P/ASX 200 Index (ASX: XJO) gold stock Ramelius Resources Ltd (ASX: RMS) is charging higher today. Ramelius shares closed yesterday trading for $2.30. In morning trade on Thursday, shares are swapping hands for $2.41 apiece, up 4.8%....

Healthcare and medical manufacturing in Australia is gaining momentum supported by initiatives from federal and state governments CSL, IDT Australia, Optiscan and Trajan Group among healthcare companies with manufacturing facilities in Mel...

The S&P/ASX 200 Index (ASX: XJO) had a nervous yet positive end to the trading week this Friday. After yesterday's drop, investors didn't seem to know what to do for most of the day, but the ASX...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

As most investors would be aware, it's been a rough few months for the stock market. Since the start of November, the S&P/ASX 200 Index (ASX: XJO) is nursing a 1.5% loss despite the 3.2% rally it has enjoyed over the past two weeks. Wit...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.35% to 7,997.6 points. Four ASX shares that are rising more than most today are listed below....

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2 Event to highlight some of ASX’s leading up-and-coming health and life sciences companies EMVision, Microba Life Sciences, Orthocell, Lumos Diagnosti...

The team at Bell Potter has been busy running the rule over the healthcare sector and has picked out a number of stocks that it believes are attractive options right now. Let's see what the broker is recommending investors buy now: Clinuve...

Orthocell (ASX:OCC) is set to kick off sales in Germany, Austria and Switzerland for its dental guided bone and tissue regeneration product Striate+, gaining exposure to a market valued over $1 billion.  Watch the video to hear more.   Thi...

Orthocell (ASX: OCC) has achieved the first sales of its dental guided bone and tissue regeneration product Striate+ into new markets in Germany, Austria and Switzerland through exclusive global distribution partner BioHorizons Implant Syst...

In afternoon trade S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.8% to 8,004.2 points. Four ASX shares that are rising more than most today are listed below. Here...

It’s up and go time for LTR in the US market All the budget healthcare news – and it’s a short item Prescient launches phase 2a study for a rare blood cancer   The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR P...

It has been a rough stretch for many ASX lithium stocks recently, but one name is bucking the trend in a big way today. Vulcan Energy Resources Ltd (ASX: VUL) shares are surging higher in Tuesday thanks to some big news. At the time of writ...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

It was a rather unremarkable day for the S&P/ASX 200 Index (ASX: JXO) and most ASX 200 shares this Tuesday. By the time trading wrapped up, the ASX 200 had advanced by a nervous 0.08%, leaving the index at 7,860.4 points. But it was a v...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the skinny on Orthocell (ASX:OCC) latest advancement for Striate+, landing market entry into Singapore through its dist...

Highlights: ASX200 registered a marginal gain, reflecting mixed sector performance. Utilities led gains, while Discretionary and Financial sectors saw declines. Key corporate updates influenced stock movements across multipl...

The ASX200 pared early gains to close up by a sliver of less than a tenth of a percent at 7860 points. Utilities was the best performing sector, up 1.7%, followed by Real Estate, up 0.7%, and Energy, up 0.6%. Discretionay was the wors...

The S&P/ASX 200 Index (ASX: XJO)'s recovery continued this Tuesday, with the index building on the gains we saw yesterday to push slightly higher. By the time the markets closed, the ASX 200 had...

The right portfolio of ASX passive income shares can offer a big boost to your retirement lifestyle. And the sooner you start building up that income portfolio, the bigger that boost is likely to be. If you're 30 and aim to retire at 67, th...

Orthocell (ASX: OCC) has received regulatory approval from Singapore’s Health Sciences Authority to commence regional sales of its dental membrane product Striate+ for use in guided bone and tissue regeneration applications. The company sai...

The S&P/ASX 200 Index (ASX: XJO) is on form again and pushing higher on Tuesday. In afternoon trade, the benchmark index is up 0.2% to 7,870.2 points. Four ASX shares that are rising more than most today are listed below. Here's why th...

S&P/ASX 200 Index (ASX: XJO) gold stock West African Resources Ltd (ASX: WAF) is shining bright today. Again. West African Resource shares closed yesterday trading for $2.24. In early afternoon trade on Tuesday, shares are changing han...

Telix Pharmaceuticals’ Brazilian win marks its first foray into the South American market Orthocell gains approval to sell its dental guided bone regeneration product in Singapore Sigma Healthcare: great prospects, a pity about the valuati...

A strong performance from a range of ASX shares today sees the All Ordinaries Index (ASX: XAO) up 0.34% at the time of writing. With the All Ords now in the green for the third consecutive day running, the Aussie stock market is edging furt...

ASX 200 healthcare share Clarity Pharmaceuticals Ltd (ASX: CU6) is the strongest gainer of the S&P/ASX 200 Index (ASX: XJO) on Tuesday. Clarity Pharmaceuticals shares rocketed 13.8% to an intraday high of $2.89 in early trading toda...

Gold has been one of the most interesting corners of the investment markets to watch recently. Whether it be raw bullion prices or the performance of gold exchange-traded funds (ETFs) on the ASX, these investments have been on a tear of lat...